The chart is not accessible to screen readers. Please switch to the table view to access the data.
Advertisement
Advertisement
Number of multiple sclerosis drugs in development in the United States as of July 2014
Multiple sclerosis management products in development in the U.S. 2014
This statistic displays the number of products in development for multiple sclerosis (MS) management as of 2014, in the United States. As of July 2014, 15 such products were in Phase 2 of development. There are about 350,000 to 500,000 people in the country that are diagnosed with the disease. MS is a disease that damages nerve cells in the brain and spinal cord which disrupts the ability of the nervous system to communicate with the body.
* For commercial use only
Basic Account
For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
- Free Statistics
Based on your interests
Starter Account
For single users
$199 USD
per month, billed annually
1
- Free Statistics
- Premium Statistics
Professional Account
For teams of up to 99 users
Talk to sales for pricing
- Free + Premium Statistics
- Reports
- Market ÌÇÐÄÆƽâ°æ
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Other statistics that may interest you Statistics on
About the industry
10
- Premium Statistic Leading MS pharmaceutical drugs in the U.S. by revenue 2013
- Basic Statistic Alzheimer’s disease drugs in trial phase II by mechanism of action 2025
- Basic Statistic Phase 2 and 3 trials in Alzheimer’s drug development by region 2025
- Basic Statistic Alzheimer’s disease drugs in trial phase III by mechanism of action 2025
- Basic Statistic Number of active trials in Alzheimer's Disease pipeline 2022, by product type
- Basic Statistic Key categories in orphan drug pipeline worldwide 2022
- Basic Statistic Key technologies in Alzheimer's Disease clinical trials 2021
- Premium Statistic Leading orphan drugs based on R&D phase III cost 2015
- Premium Statistic Orphan vs. non-orphan drugs median cost per patient per year 2014-2018
- Premium Statistic Share of active trials for Alzheimer's Disease pipeline 2022, by product type
About the region
10
- Basic Statistic Revenue from top 20 women health products in the U.S. 2016
- Basic Statistic Satisfaction or desire for received pharmaceutical services in the U.S. 2013
- Premium Statistic Number of FDA approved orphan designations in the U.S. 2000-2014
- Premium Statistic Most abused prescription drugs by dispensed prescriptions U.S. 2013
- Basic Statistic Top five services from pharma companies for U.S. patients 2013
- Premium Statistic Number of medicines in development for heart disease and stroke by type 2018
- Basic Statistic Biosimilars in development and approved by FDA 2019, by manufacturer
- Basic Statistic Forecast major categories of U.S. healthcare expenditures 2015-2020
- Premium Statistic Medicinal market growth worldwide including rebates 2009-2018
- Premium Statistic Type 2 diabetes clinical pipeline in the U.S. in 2018, by type and phase
Selected statistics
10
- Premium Statistic Orphan vs. non-orphan pipeline sales forecast worldwide 2025-2030
- Basic Statistic Pharmaceutical products in pipeline for disease in developing countries 2024
- Basic Statistic Worldwide share of orphan drug sales by therapy category 2030
- Basic Statistic Distribution of COVID-19 vaccines worldwide by mechanism and phase 2022
- Basic Statistic Share of orphan medicines in R&D pipeline worldwide 2023, by phase
- Premium Statistic Pharma products in pipeline for top 10 diseases in developing countries 2024
- Basic Statistic Revenue of top 20 neurology products in the U.S. 2016
- Premium Statistic Most commonly used prescription drugs Australia FY 2023
- Basic Statistic New pharmaceuticals EMA approved and availability in Sweden 2024
- Premium Statistic Most expensive prescription drugs Australia FY 2023, by cost to government
Other regions
10
- Basic Statistic Indications in clinical trials for cell and gene therapies worldwide 2022
- Premium Statistic Clinical trials initiated worldwide 2018-2024
- Basic Statistic Clinical trials initiated worldwide 2018-2024, by trial phase
- Premium Statistic Percentage return on R&D among large cap biopharma companies 2010-2020
- Basic Statistic Members of EFPIA's pharmaceutical exports and imports 1990-2025
- Premium Statistic Market revenue from type 2 diabetes pharmaceuticals by region 2012-2022
- Premium Statistic Sales revenue Celltrion 2014-2024
- Premium Statistic Distribution of Celltrion's revenue Q3 2024, by product
- Basic Statistic Orphan and non-orphan drugs in the pipeline worldwide 2021
- Premium Statistic Distribution of Celltrion's bioproduct revenue Q3 2024
Related statistics
10
- Basic Statistic Clinical drug trials started worldwide 2018-2023, by key therapeutic area
- Basic Statistic Expenditure worldwide on diabetes by market 2013-2018
- Premium Statistic Members of EFPIA's pharmaceutical market value 2000-2025
- Basic Statistic Top global orphan drugs by revenue 2018
- Premium Statistic Small molecules facing loss of developed market exclusivity 2011-2020
- Premium Statistic Veterinary vaccines market share worldwide in 2016, by technology
- Premium Statistic Pharmaceutical expenditure forecast worldwide by country 2030
- Basic Statistic Pharmaceutical sector expenditure forecast worldwide by country 2060
- Basic Statistic Pharma revenue share worldwide 2017, by country
- Basic Statistic Usage rate of top drug classes prescribed to seniors in Canada by age 2021
Further Content: You might find this interesting as well
* For commercial use only
Basic Account
For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
- Free Statistics
Based on your interests
Starter Account
For single users
$199 USD
per month, billed annually
1
- Free Statistics
- Premium Statistics
Professional Account
For teams of up to 99 users
Talk to sales for pricing
- Free + Premium Statistics
- Reports
- Market ÌÇÐÄÆƽâ°æ
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Catamaran. (July 1, 2014). Number of multiple sclerosis drugs in development in the United States as of July 2014 [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 24, 2026, from /statistics/372305/ms-products-in-development-for-management-in-the-us/
Catamaran. "Number of multiple sclerosis drugs in development in the United States as of July 2014 ." Chart. July 1, 2014. ÌÇÐÄÆƽâ°æ. Accessed July 24, 2026. /statistics/372305/ms-products-in-development-for-management-in-the-us/
Catamaran. (2014). Number of multiple sclerosis drugs in development in the United States as of July 2014 . ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 24, 2026. /statistics/372305/ms-products-in-development-for-management-in-the-us/
Catamaran. "Number of Multiple Sclerosis Drugs in Development in The United States as of July 2014 ." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 1 Jul 2014, /statistics/372305/ms-products-in-development-for-management-in-the-us/
Catamaran, Number of multiple sclerosis drugs in development in the United States as of July 2014 ÌÇÐÄÆƽâ°æ, /statistics/372305/ms-products-in-development-for-management-in-the-us/ (last visited July 24, 2026)
Number of multiple sclerosis drugs in development in the United States as of July 2014 [Graph], Catamaran, July 1, 2014. [Online]. Available: /statistics/372305/ms-products-in-development-for-management-in-the-us/
Advertisement